- On May 15, 2026, Inspire Medical Systems’ Chief Product and Innovation Officer, John Rondoni, sold 2,641 shares at a weighted average price of US$43.28, and the company cut its 2026 guidance amid reimbursement and coding uncertainty linked to a new Wisconsin MAC directive and the WISER Medicare pilot.
- This combination of insider selling and heightened concern over Medicare coding and reimbursement for hypoglossal nerve stimulation has sharpened investor focus on Inspire’s earnings visibility and the durability of its current business model.
- Now we’ll examine how these reimbursement and coding uncertainties may reshape Inspire Medical Systems’ previously supportive investment narrative.
We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Inspire Medical Systems Investment Narrative Recap
To own Inspire Medical Systems, you need to believe that hypoglossal nerve stimulation remains a viable, reimbursable therapy for obstructive sleep apnea despite rising payer scrutiny. Right now, the key near term catalyst is greater clarity from Medicare and MACs on coding and coverage, while the biggest risk is that current reimbursement uncertainty persists or worsens, which could weigh on earnings visibility more than the recent insider sale itself.
The most relevant recent development is Inspire’s sharp cut to its 2026 guidance, citing the Wisconsin MAC directive and WISER Medicare pilot as sources of coding confusion and reimbursement risk. This reset frames how you might interpret John Rondoni’s May 15 share sale and puts extra weight on upcoming billing and policy updates as potential triggers for either renewed confidence or further estimate pressure.
Yet beneath the recent volatility, a less obvious risk that investors should be aware of is...
Read the full narrative on Inspire Medical Systems (it's free!)
Inspire Medical Systems' narrative projects $1.1 billion revenue and $97.5 million earnings by 2029. This implies 8.0% yearly revenue growth but a $47.9 million decrease in earnings from $145.4 million today.
Uncover how Inspire Medical Systems' forecasts yield a $79.42 fair value, a 81% upside to its current price.
Exploring Other Perspectives
The most pessimistic analysts already assumed almost flat revenue at about US$904.2 million and earnings falling to roughly US$47.7 million, so this new reimbursement shock could push their already cautious view on billing risks even further, while you weigh how different these expectations are from the more optimistic scenarios.
Explore 9 other fair value estimates on Inspire Medical Systems - why the stock might be worth just $45.00!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Inspire Medical Systems research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Inspire Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Inspire Medical Systems' overall financial health at a glance.
Want Some Alternatives?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
- AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com